Article

FMRP targets distinct mRNA sequence elements to regulate protein expression

  • Nature volume 492, pages 382386 (20 December 2012)
  • doi:10.1038/nature11737
  • Download Citation
Received:
Accepted:
Published:

Abstract

Fragile X syndrome (FXS) is a multi-organ disease that leads to mental retardation, macro-orchidism in males and premature ovarian insufficiency in female carriers. FXS is also a prominent monogenic disease associated with autism spectrum disorders (ASDs). FXS is typically caused by the loss of fragile X mental retardation 1 (FMR1) expression, which codes for the RNA-binding protein FMRP. Here we report the discovery of distinct RNA-recognition elements that correspond to the two independent RNA-binding domains of FMRP, in addition to the binding sites within the messenger RNA targets for wild-type and I304N mutant FMRP isoforms and the FMRP paralogues FXR1P and FXR2P (also known as FXR1 and FXR2). RNA-recognition-element frequency, ratio and distribution determine target mRNA association with FMRP. Among highly enriched targets, we identify many genes involved in ASD and show that FMRP affects their protein levels in human cell culture, mouse ovaries and human brain. Notably, we discovered that these targets are also dysregulated in Fmr1−/− mouse ovaries showing signs of premature follicular overdevelopment. These results indicate that FMRP targets share signalling pathways across different cellular contexts. As the importance of signalling pathways in both FXS and ASD is becoming increasingly apparent, our results provide a ranked list of genes as basis for the pursuit of new therapeutic targets for these neurological disorders.

  • Subscribe to Nature for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Accessions

Primary accessions

Gene Expression Omnibus

Data deposits

Data sets have been submitted to gene expressionomnibus (GEO) under the accession code GSE39686

References

  1. 1.

    et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905–914 (1991)

  2. 2.

    et al. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 252, 1711–1714 (1991)

  3. 3.

    et al. Abnormal pattern detected in fragile-X patients by pulsed-field gel electrophoresis. Nature 349, 624–626 (1991)

  4. 4.

    , , & The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74, 291–298 (1993)

  5. 5.

    , , & FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262, 563–566 (1993)

  6. 6.

    et al. Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein. J. Biol. Chem. 273, 15521–15527 (1998)

  7. 7.

    et al. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107, 489–499 (2001)

  8. 8.

    et al. Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nature Genet. 4, 244–251 (1993)

  9. 9.

    et al. Alternative splicing in the fragile X gene FMR1. Hum. Mol. Genet. 2, 399–404 (1993)

  10. 10.

    et al. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nature Genet. 3, 31–35 (1993)

  11. 11.

    , , , & Essential role for KH domains in RNA binding: impaired RNA binding by a mutation in the KH domain of FMR1 that causes fragile X syndrome. Cell 77, 33–39 (1994)

  12. 12.

    et al. FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol. Cell 1, 109–118 (1997)

  13. 13.

    , , , & A nuclear role for the Fragile X mental retardation protein. EMBO J. 15, 5408–5414 (1996)

  14. 14.

    , , & Transport of Drosophila fragile X mental retardation protein-containing ribonucleoprotein granules by kinesin-1 and cytoplasmic dynein. Proc. Natl Acad. Sci. USA 101, 17428–17433 (2004)

  15. 15.

    et al. The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules. Hum. Mol. Genet. 16, 3047–3058 (2007)

  16. 16.

    , , , & A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev. Cell 14, 926–939 (2008)

  17. 17.

    et al. The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. Hum. Mol. Genet. 6, 1465–1472 (1997)

  18. 18.

    & FMR1: a gene with three faces. Biochim. Biophys. Acta 1790, 467–477 (2009)

  19. 19.

    , , , & Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis. Adv. Exp. Med. Biol. 970, 517–551 (2012)

  20. 20.

    , & Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37, 178–195 (2012)

  21. 21.

    , , & Fragile X syndrome and targeted treatment trials. Results Probl. Cell Differ. 54, 297–335 (2012)

  22. 22.

    et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247–261 (2011)

  23. 23.

    & Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411–429 (2011)

  24. 24.

    & The state of synapses in fragile X syndrome. Neuroscientist 15, 549–567 (2009)

  25. 25.

    & Fragile X syndrome and autism at the intersection of genetic and neural networks. Nature Neurosci. 9, 1221–1225 (2006)

  26. 26.

    et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107, 477–487 (2001)

  27. 27.

    & Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201–214 (2008)

  28. 28.

    et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141, 129–141 (2010)

  29. 29.

    et al. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature 456, 464–469 (2008)

  30. 30.

    , , , & Identification of RNA–protein interaction networks using PAR-CLIP. Wiley Interdiscip. Rev. RNA 3, 159–177 (2012)

  31. 31.

    et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl Acad. Sci. USA 101, 6062–6067 (2004)

  32. 32.

    et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470–476 (2008)

  33. 33.

    et al. A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nature Methods 8, 559–564 (2011)

  34. 34.

    et al. PARalyzer: definition of RNA binding sites from PAR-CLIP short-read sequence data. Genome Biol. 12, R79 (2011)

  35. 35.

    et al. Evidence-ranked motif identification. Genome Biol. 11, R19 (2010)

  36. 36.

    & FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5, e52 (2007)

  37. 37.

    et al. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J. 20, 4803–4813 (2001)

  38. 38.

    , & Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol. Cell. Biol. 19, 7925–7932 (1999)

  39. 39.

    , & The pathophysiology of fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci. 35, 417–443 (2012)

  40. 40.

    et al. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 140, 704–716 (2010)

  41. 41.

    et al. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch–Belgian Fragile X Consortium. Cell 78, 23–33 (1994)

  42. 42.

    et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 30, 10624–10638 (2010)

  43. 43.

    et al. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30, 694–702 (2010)

  44. 44.

    , & Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63–68 (2011)

  45. 45.

    , , , & Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J. Neurosci. 31, 8862–8869 (2011)

  46. 46.

    et al. Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the ΔRG mouse model of tuberous sclerosis complex. Neurobiol. Dis. 45, 1101–1110 (2012)

  47. 47.

    et al. in Handbook of RNA Biochemistry Vol. 1 (eds , , & ) (Wiley-VCH, 2013)

  48. 48.

    , & DNA familial binding profiles made easy: comparisons of various motif alignment and clustering strategies. PLoS Comp. Biol. 3, e61 (2007)

  49. 49.

    et al. Molecular characterization of human Argonaute-containing ribonucleoprotein complexes and their bound target mRNAs. RNA 14, 2580–2596 (2008)

  50. 50.

    , , & affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307–315 (2004)

Download references

Acknowledgements

Human tissue was obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore. We would like to thank the following members of the Tuschl laboratory for their support and assistance: G. Wardle, N. Renwick and I. Ben-Dov. We would like to thank J. Keene for his advice throughout the project. We would like to acknowledge M. Khorshid, L. Burger and M. Zavolan for analysing PAR-CLIP data at the initial stages of the project and discussions. We would like to thank the Memorial Sloan-Kettering Cancer Center in-situ core for their assistance with the mouse histology. Finally, we would like to express our appreciation to all members of the Tuschl laboratory for their assistance and collegiality. This work was supported, in part, by the following agencies: NIH/NCRR/RU CCTS (M.A., UL1RR024143), NSF (U.O., MCB-0822033), Simons Foundation Autism Research Initiative (T.T., CEN5300891) and NIH (T.T., R01 MH080442; Z.W., K08 HD068546).

Author information

Author notes

    • Neelanjan Mukherjee
    •  & Uwe Ohler

    Present address: The Berlin Institute for Medical Systems Biology, Max Delbrück Center, 13125 Berlin-Buch, Germany (N.M. and U.O.).

Affiliations

  1. Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, New York, New York 10065, USA

    • Manuel Ascano
    • , Pradeep Bandaru
    • , Jason B. Miller
    • , Jeffrey D. Nusbaum
    • , Mathias Munschauer
    • , Markus Hafner
    • , Zev Williams
    •  & Thomas Tuschl
  2. Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA

    • Neelanjan Mukherjee
    • , David L. Corcoran
    •  & Uwe Ohler
  3. Program for Early and Recurrent Pregnancy Loss, Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein College of Medicine, Bronx, New York 10461, USA

    • Christine Langlois
    •  & Zev Williams
  4. Genomics Resource Center, The Rockefeller University, New York, New York 10065, USA

    • Scott Dewell

Authors

  1. Search for Manuel Ascano in:

  2. Search for Neelanjan Mukherjee in:

  3. Search for Pradeep Bandaru in:

  4. Search for Jason B. Miller in:

  5. Search for Jeffrey D. Nusbaum in:

  6. Search for David L. Corcoran in:

  7. Search for Christine Langlois in:

  8. Search for Mathias Munschauer in:

  9. Search for Scott Dewell in:

  10. Search for Markus Hafner in:

  11. Search for Zev Williams in:

  12. Search for Uwe Ohler in:

  13. Search for Thomas Tuschl in:

Contributions

M.A. designed, executed, supervised and interpreted experiments. N.M., P.B. and D.L.C. carried out the sequence alignment, annotation and PARalyzer pipeline. N.M. and P.B. performed the computational analysis on the RIP-chip. M.A., J.B.M. and J.D.N. purified FMRP proteins, performed the EMSAs and carried out the quantitative western blots and analyses. M.A. and M.M. performed the RIP-chips. S.D. assisted in the Illumina sequencing of all PAR-CLIP libraries. M.H. helped in the initial PAR-CLIP experiments. C.L. and Z.W. carried out and analysed mouse experiments. U.O. supervised computational efforts. T.T. supervised and helped in the design of experiments. M.A. and T.T. wrote the manuscript.

Competing interests

T.T. is co-founder and scientific advisor to Alnylam Pharmaceuticals and Regulus Therapeutics.

Corresponding authors

Correspondence to Uwe Ohler or Thomas Tuschl.

Supplementary information

PDF files

  1. 1.

    Supplementary Figures

    This file contains Supplementary Figures 1-10.

Zip files

  1. 1.

    Supplementary Data

    This zipped file contains Supplementary Tables 1 and 3-7.

  2. 2.

    Supplementary Data

    This zipped file contains Supplementary Tables 2a and 2b.

  3. 3.

    Supplementary Data

    This zipped file contains Supplementary Tables 2c and 2d.

  4. 4.

    Supplementary Data

    This zipped file contains Supplementary Table 2e.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.